• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Portfolio

Pandemic Preparedness 

Pandemic Response Box

Home > Research and development > Portfolio

Pandemic Preparedness

Pandemic Response Box

objective

Accelerate the discovery of new treatments for life-threatening pandemic diseases by providing researchers free access to 400 diverse compounds.

project start
2019

current phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 1 Mar 2022

Launched in 2019 by Medicines for Malaria Venture (MMV) and DNDi, the Pandemic Response Box is a collaborative project that aims to accelerate the discovery of new treatments for life-threatening pandemic diseases by providing researchers free access to 400 diverse compounds.

Disease experts selected the Pandemic Response Box’s collection of 201 antibacterial, 153 antiviral, and 46 antifungal compounds for screening against infectious and neglected diseases. The compounds are in various phases of drug discovery or development. In return for receiving the drug-like molecules free of charge, researchers agree to make their screening results publicly available and to publish their findings in an open access journal within two years following data generation.

The goal is to help shorten the time between the emergence of a new pandemic and the availability of new drugs to treat it. History has repeatedly shown that saving time, saves lives.

Graeme Bilbe, Former R&D Director, DNDi

Open and collaborative approaches to medical innovation

The Pandemic Response Box is one of several MMV and DNDi open science projects, which encourage collaboration and transparency in drug development research.

How to order

The Pandemic Response Box is now coordinated by MMV. More details on the box and how to order it can be found on the web page.

Project update

September 2019

In the first 18 months of the project, 116 labs received the Pandemic Response Box, of which 13 are evaluating compounds for activity against COVID-19.

Factsheet

Coverpage of the Pandemic Response Box Factsheet

Pandemic Response Box
2019

English

News & resources

  • 14 March 2022 – The pandemic response box ─ accelerating drug discovery efforts after disease outbreaks, ACS Infectious Diseases
  • 4 February 2022 – Screening the Pandemic Response Box identified benzimidazole carbamates, olorofim, and ravuconazole as promising drug candidates for the treatment of eumycetoma, PLOS Neglected Tropical Diseases
  • 10 November 2021 – How collaboration and new drugs could beat malaria, BBC
  • 12 January 2021 – SA researchers may have found a way to cure malaria, The Citizen
  • 29 January 2019 – Pandemic Response Box factsheet
  • 29 January 2019 – MMV and DNDi create a response box to foster R&D for pandemic diseases, Pharmaceutical Technology

Partners

  • Medicines for Malaria Venture (MMV), Switzerland
Loading…
  • Medicines for Malaria Venture (MMV)
  • ,Switzerland
  • Medicines for Malaria Venture (MMV), Switzerland

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License